Status
Conditions
Treatments
About
A prospective, multicenter, blind randomized (2:1) controlled study comparing the International Prostate Symptom Score (IPSS) of the Active arm to the IPSS of the control arm at the 3 months follow-up and active arm IPSS score change from time zero to 12 months. Patients in the active arm undergo Butterfly device treatment. Patients in the control arm undergo a sham rigid cystoscopy procedure
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Known sensitivity to Nickel.
Current urinary retention
Urinary stress incontinence (sphincter)
Biopsy of the prostate within the last 6 weeks
Baseline PSA > 10 ng/mL or confirmed or suspected prostate cancer. Patients with a PSA level above 2.5 ng/mL, in which free PSA is < 25% of total PSA in whom cancer was not ruled out by biopsy.
Chronic prostatitis, recurrent prostatitis, chronic pelvic pain syndrome (CPPS), or painful bladder syndrome within the past 12 months
Obstructing intraprostatic median lobe (e.g., more than 10mm intravesical prostatic protrusion).
Urethral stricture, meatal stenosis, or bladder neck stricture - either current or recurrent.
Anatomical anomalies that will not accommodate the retractor, as determined by cystoscopy (e.g., prostatic urethral length to height geometry, absence of bladder neck)
Prior surgery or minimal invasive procedure of prostate (brachytherapy and PAE patients are not excluded if they show significant obstruction in urodynamic test and cystoscopy shows no significant fibrosis).
Currently active bladder tumor or intravesical instillation.
History of other diseases causing voiding dysfunction including urinary retention (e.g., uncontrolled diabetes, diagnosis of neurogenic or atonic bladder, Parkinson's disease, multiple sclerosis, etc.).
Suspected Neurogenic or atonic urinary bladder.
Suspected Polyuria/Nocturnal Polyuria.
Suspected overactive bladder
High bladder neck with the absence of lateral lobe encroachment indicating a high likelihood of primary bladder neck obstruction as determined by the Investigator
Urethral pathology: diverticula, strictures, tumors, fistula.
Acute clinically Significant urinary tract infection.
Uncontrolled bleeding disorders.
Active stone disease (urinary stone increase in size during the last 3 months/ stone passage during the last 3 months/ presence of cystolithiasis)
Taking 5 alpha reductase inhibitors within 6 months of baseline evaluation
Taking one of the following within 2 weeks of baseline evaluation:
Taking androgens, unless eugonadal state for at least 2 months or greater as documented by the Investigator
Taking Gonadotrophin releasing hormone analogues within 12 months of baseline evaluation
Taking one of the following within 24 hours of pre-treatment (baseline) evaluation:
phenylephrine, or, pseudoephedrine,
One of the following baseline test results, taken from a single uroflowmetry reading:
Inmates, patient with physical, psychological (such as developmentally delayed adults), or medical impairment that might prevent study completion or would confound study results (including patient questionnaires) in the judgment of the Investigator
Currently participating in another investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the endpoints of this study.
Primary purpose
Allocation
Interventional model
Masking
222 participants in 3 patient groups
Loading...
Central trial contact
Vardit Segal, Ph.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal